Liquidia (NASDAQ:LQDA) Posts Quarterly Earnings Results, Misses Expectations By $0.02 EPS

Liquidia (NASDAQ:LQDA) issued its earnings results on Wednesday. The company reported $0.74 earnings per share for the quarter, missing the consensus estimate of $0.76 by ($0.02), FiscalAI reports. Liquidia had a net margin of 7.74% and a return on equity of 46.82%. The business had revenue of $171.68 million for the quarter, compared to analyst estimates of $168.48 million. During the same quarter last year, the firm posted ($0.49) earnings per share. Liquidia’s revenue was up 1842.1% on a year-over-year basis.

Here are the key takeaways from Liquidia’s conference call:

• YUTREPIA continued strong commercial growth, with approximately 5,900 unique prescriptions, more than 5,000 patients started, and over 1,100 prescribing physicians as of July 31. Q2 net product sales reached $170.4 million, up 31% sequentially, and YUTREPIA represented nearly 30% of the inhaled treprostinil market.
• Liquidia reported improving profitability and cash generation, including $74.7 million of net income, $96.3 million of adjusted EBITDA, and $284.2 million in cash and equivalents. Management reiterated confidence in exceeding $1 billion in net revenue in 2027 while continuing to fund pipeline investments.
• The company is expanding its commercial organization and believes substantial opportunity remains in community-based PAH and PH-ILD diagnosis and treatment, as well as switches from competing inhaled, oral, and parenteral prostacyclin therapies. Payer access was described as broadly available and generally at parity.
• Liquidia plans significant R&D expansion, with second-half 2026 R&D expense expected to be double the first half and additional increases anticipated in 2027. The company has 10 YUTREPIA and L606 studies underway or planned, including the Phase III RESPIRE trial for twice-daily L606 and future studies in Raynaud’s phenomenon and progressive pulmonary fibrosis.
• The company is still awaiting a decision in the ’327 litigation, with management saying a ruling could come at any time and acknowledging possible outcomes including royalties or injunctive relief if the decision goes against Liquidia.

Liquidia Price Performance

NASDAQ:LQDA traded down $8.26 on Wednesday, reaching $79.79. The stock had a trading volume of 2,159,596 shares, compared to its average volume of 1,768,413. The company has a quick ratio of 2.03, a current ratio of 2.22 and a debt-to-equity ratio of 1.18. The company has a market capitalization of $7.10 billion, a P/E ratio of 569.97 and a beta of 0.58. Liquidia has a 1-year low of $21.15 and a 1-year high of $93.61. The stock has a fifty day moving average price of $77.76 and a 200-day moving average price of $54.51.

Analysts Set New Price Targets

A number of brokerages have commented on LQDA. Wall Street Zen cut shares of Liquidia from a “strong-buy” rating to a “buy” rating in a research note on Saturday, June 27th. Piper Sandler set a $129.00 price objective on Liquidia in a research note on Friday, July 24th. Jefferies Financial Group reissued a “buy” rating and issued a $60.00 target price on shares of Liquidia in a report on Monday, May 11th. Stephens set a $130.00 target price on Liquidia in a research report on Friday, July 24th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Liquidia in a research note on Friday, July 17th. Three analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $86.18.

Insider Buying and Selling

In other news, Director Stephen M. Bloch sold 242,269 shares of the business’s stock in a transaction that occurred on Thursday, June 11th. The stock was sold at an average price of $70.43, for a total value of $17,063,005.67. Following the transaction, the director directly owned 1,176,184 shares of the company’s stock, valued at $82,838,639.12. The trade was a 17.08% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Paul B. Manning sold 200,000 shares of the firm’s stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $63.91, for a total value of $12,782,000.00. Following the sale, the director directly owned 716,311 shares of the company’s stock, valued at $45,779,436.01. This represents a 21.83% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 1,781,861 shares of company stock valued at $124,407,112 in the last quarter. 25.60% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Liquidia

Hedge funds have recently added to or reduced their stakes in the stock. TCG Crossover Management LLC bought a new stake in shares of Liquidia during the third quarter worth approximately $38,887,000. MPM Bioimpact LLC boosted its stake in Liquidia by 600.4% in the fourth quarter. MPM Bioimpact LLC now owns 1,400,869 shares of the company’s stock valued at $48,316,000 after acquiring an additional 1,200,869 shares during the last quarter. Voloridge Investment Management LLC acquired a new stake in Liquidia during the 3rd quarter worth $12,571,000. Invesco Ltd. grew its holdings in Liquidia by 428.3% during the 4th quarter. Invesco Ltd. now owns 420,621 shares of the company’s stock worth $14,507,000 after acquiring an additional 341,009 shares during the period. Finally, First Trust Advisors LP bought a new stake in shares of Liquidia during the 4th quarter valued at $10,587,000. Institutional investors own 64.54% of the company’s stock.

Key Liquidia News

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: YUTREPIA sales accelerated. Net product sales reached approximately $170.4 million in the second quarter, up 31% from the first quarter. Liquidia reported roughly 5,900 unique prescriptions and more than 5,000 patients treated since the product launched in June 2025. Liquidia Corporation Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Profitability and cash generation improved. Liquidia posted $171.7 million in revenue, $74.7 million in net income and $96.3 million in adjusted EBITDA, marking its fourth consecutive quarter of increasing profitability. Cash and equivalents rose to approximately $284.2 million from $190.7 million at the end of 2025. Liquidia Q2 Net Income Reaches $74.7 Million As YUTREPIA Sales Rise
• Positive Sentiment: Management maintained its long-term growth outlook. Liquidia reaffirmed its target of more than $1 billion in net revenue in 2027 and is advancing 10 clinical studies involving YUTREPIA and the L606 inhaled treprostinil program.
• Neutral Sentiment: Institutional interest remains mixed but generally supportive. Recent filings showed major investors including BlackRock and State Street adding shares, although some funds reduced their positions.
• Negative Sentiment: Adjusted expectations contributed to the selloff. Diluted EPS of $0.74 was slightly below the approximately $0.76 analyst consensus cited by several reports, despite revenue exceeding expectations. Another estimate source placed consensus at $0.70, highlighting differences among analyst forecasts. Liquidia shares fall after second-quarter earnings miss despite revenue growth
• Negative Sentiment: Spending is increasing. Research and development expenses rose to $17.2 million from $6.0 million a year earlier as Liquidia funds the Phase 3 L606 program. The company’s elevated valuation also leaves less room for disappointing results.
• Negative Sentiment: Insider selling is a potential overhang. Reported insider activity over the past six months consisted overwhelmingly of sales, including transactions by senior executives, with only one reported purchase.

About Liquidia

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).